Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902219-25-000097
Filing Date
2025-02-10
Accepted
2025-02-10 10:25:39
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10770
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 4406
  Complete submission text file 0000902219-25-000097.txt   17239
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Subject) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91636 | Film No.: 25604189
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)